These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15232748)

  • 21. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of heroin-dependent persons with antagonists: current status.
    Renault PF
    NIDA Res Monogr; 1981; 28():11-22. PubMed ID: 6791000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naltrexone for heroin dependence treatment in St. Petersburg, Russia.
    Krupitsky EM; Zvartau EE; Masalov DV; Tsoi MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
    J Subst Abuse Treat; 2004 Jun; 26(4):285-94. PubMed ID: 15182893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of naltrexone to extinguish opioid-conditioned responses.
    O'Brien CP; Childress AR; McLellan AT; Ternes J; Ehrman RN
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):53-6. PubMed ID: 6381473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year follow-up of opiate addicts with naltrexone and behavior therapy.
    Rawson RA; Tennant FS
    NIDA Res Monogr; 1984 Mar; 49():289-95. PubMed ID: 6434974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.
    Messinis L; Lyros E; Andrian V; Katsakiori P; Panagis G; Georgiou V; Papathanasopoulos P
    Hum Psychopharmacol; 2009 Oct; 24(7):524-31. PubMed ID: 19650155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
    Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
    Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of naltrexone in the treatment of opiate addicts. Efficacy and indications for type categories].
    Faro G; Jarre P; Martucci M; Sargiotto A; Eandi M
    Clin Ter; 1991 Nov 15-30; 139(3-4):93-9. PubMed ID: 1837256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming opioid blockade from depot naltrexone (Prodetoxon).
    Kruptisky EM; Burakov AM; Tsoy MV; Egorova VY; Slavina TY; Grinenko AY; Zvartau EE; Woody GE
    Addiction; 2007 Jul; 102(7):1164-5. PubMed ID: 17498182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.
    Chen TJ; Blum K; Payte JT; Schoolfield J; Hopper D; Stanford M; Braverman ER
    Med Hypotheses; 2004; 63(3):538-48. PubMed ID: 15288384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
    Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
    J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
    Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
    Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors affecting the outcome of methadone maintenance treatment in opiate dependence.
    Kamal F; Flavin S; Campbell F; Behan C; Fagan J; Smyth R
    Ir Med J; 2007 Mar; 100(3):393-7. PubMed ID: 17491538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
    Simon DL
    Conn Med; 1996 Nov; 60(11):683-5. PubMed ID: 8979434
    [No Abstract]   [Full Text] [Related]  

  • 36. [Maintenance treatment for opiate dependence at a naltrexone clinic].
    López-Ibor Aliño JJ; Pérez de los Cobos JC; Ochoa E; Hernández Herreros M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1990; 18(5):296-305. PubMed ID: 1963258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Impulsive behaviors in opiate-dependent subjects treated with naltrexone].
    Pérez de los Cobos J; Pinet C; Ribalta E; Trujols J; Casas M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1994; 22(6):254-60. PubMed ID: 7887206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone for heroin addiction: encouraging results from Italy.
    Schifano F; Marra R
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):144-6. PubMed ID: 2338367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.